Hot Takes
Fast editorial commentary on emerging health and medical research. Hot Takes are published faster than the standard medical-review cycle so we can keep up with news that matters to people thinking about their lab work. Each one is clearly labeled and dated. To bring you information as quickly as possible, we use AI to monitor news sources and to assist in drafting these articles.
- Hot TakePublished September 9, 2026
Pelacarsen Misses Primary Endpoint in Lp(a)HORIZON Trial
Editorial commentary on Novartis, September 4, 2026
Novartis reported that pelacarsen lowered Lp(a) but did not meet the primary endpoint across the overall Lp(a)HORIZON trial population.
- Hot TakePublished September 3, 2026
Menstrual Cycle Tied to Glucose Swings in Type 1 Diabetes
Editorial commentary on Healio Endocrinology, September 1, 2026
An observational study of 77 adults with type 1 diabetes using automated insulin delivery found cycle-phase shifts in modeled insulin sensitivity and glucose metrics.
- Hot TakePublished August 27, 2026
FDA Authorizes First Combined Glucose and Ketone Monitor
Editorial commentary on U.S. Food and Drug Administration, August 25, 2026
FDA authorized Abbott's Libre Duo 10 Day system, the first US wearable to continuously monitor ketones and the first device to track glucose and ketones together.
- Hot TakePublished August 25, 2026
FDA Posts Recall for One Lot of Thyroid Tablets
Editorial commentary on U.S. Food and Drug Administration, August 24, 2026
FDA posted a company recall announcement covering one lot of Vitruvias Thyroid Tablets, USP 30 mg. The notice identifies potential superpotency found through testing.
- Hot TakePublished August 21, 2026
FDA Authorizes First Robotic Blood Draw Device
Editorial commentary on U.S. Food and Drug Administration, August 19, 2026
The FDA authorized Aletta, a supervised robotic device that automates an outpatient blood draw. The authorization could expand collection capacity, but it does not change how laboratory results are interpreted.
- Hot TakePublished August 20, 2026
An Experimental 2-HB Assay Flagged Post-Meal Dysglycemia
Editorial commentary on Diabetes Care, August 1, 2026
A 772-person study found that an experimental 2-hydroxybutyrate assay added signal beyond fasting glucose and A1c. Its low positive predictive value and commercial ties keep the result preliminary.
- Hot TakePublished August 18, 2026
A New Prostate Cancer Signal Conflicts With Earlier Evidence
Editorial commentary on Florida Atlantic University, August 12, 2026
An analysis of 17,024 U.S. men found higher prostate-cancer estimates in several higher ultra-processed-food groups. The result is observational, uses self-reported diet and cancer status, and conflicts with a 2024 meta-analysis.
- Hot TakePublished August 17, 2026
Large Utah Study Links Endometriosis With Higher Type 2 Diabetes Risk
Editorial commentary on Diabetologia / George Mason University, August 10, 2026
A Utah records study found a 46 percent higher adjusted rate of type 2 diabetes among people diagnosed with endometriosis. The finding is observational and does not create a new screening rule.
- Hot TakePublished August 16, 2026
HHS Puts $4 Million Toward Faster Syphilis Testing
Editorial commentary on U.S. Department of Health and Human Services, August 12, 2026
HHS is directing $4 million toward rapid syphilis testing in settings where a same-visit result may reduce missed follow-up. The grant does not change testing guidelines, and its effect will depend on local implementation.
- Hot TakePublished August 13, 2026
Google Says Pixel Watch Will Track Insulin Resistance Trends
Editorial commentary on Google, August 12, 2026
Google says its Health Guardian feature will use multi-week wearable data to track insulin resistance trends. It is not a diagnostic or diabetes prescreening tool, and the key wearable-only result came from 72 people.
- Hot TakePublished August 11, 2026
FDA Authorizes PCR Assay That Distinguishes Herpes, VZV, and Mpox
Editorial commentary on Federal Register / U.S. Food and Drug Administration, August 6, 2026
An August 6 Federal Register notice details FDA's July 9 emergency use authorization for a multiplex PCR assay that differentiates HSV-1, HSV-2, VZV, and mpox in lesion swabs. The assay is limited to high-complexity laboratories.
- Hot TakePublished August 10, 2026
Higher Fasting Insulin Tracked With Worsening Heart Function
Editorial commentary on Circulation: Heart Failure, August 10, 2026
A community cohort study published August 10 linked higher fasting insulin and insulin resistance with worsening diastolic function over four years. The finding is observational and does not make fasting insulin a stand-alone heart-failure test.
- Hot TakePublished August 9, 2026
Medicare Liver Fibrosis Biomarker Coverage Starts August 10
Editorial commentary on CMS Medicare Coverage Database / GENFIT, July 2, 2026
A Medicare local coverage policy taking effect August 10 creates a defined reimbursement path for qualifying blood-based liver fibrosis biomarker tests. It is narrower than routine fatty-liver screening and does not turn a standard liver panel into a fibrosis test.
- Hot TakePublished August 8, 2026
Most Higher-Risk Adults Were Above the New LDL Cholesterol Goals
Editorial commentary on JAMA, July 20, 2026
A JAMA analysis estimated that most US adults at high cardiovascular risk, and most adults with established atherosclerotic cardiovascular disease, had LDL cholesterol above the goals in the 2026 dyslipidemia guideline.
- Hot TakePublished July 8, 2026
The BMI Story Is Really a Cholesterol and Blood Pressure Story
Editorial commentary on The Lancet / STAT, July 1, 2026
A new Lancet analysis found that cholesterol and blood-pressure gaps between adults with obesity and normal BMI have narrowed after age 40. The lab-testing takeaway is not that BMI stopped mattering. It is that measured risk markers still matter because treatment and risk do not move in lockstep with body size.
- Hot TakePublished July 6, 2026
WHO Launches First Global Database Tracking STI Rates
Editorial commentary on World Health Organization, July 3, 2026
WHO's new STI Prevalence Atlas is a public data tool, not a new testing recommendation. It matters because it pulls prevalence data for five common STIs into one standardized source, while also showing how uneven global STI evidence still is.
- Hot TakePublished June 24, 2026
HHS Requests Testosterone Label Updates After TRAVERSE Trial
Editorial commentary on U.S. Department of Health and Human Services, June 18, 2026
HHS says FDA is requesting broader testosterone therapy label updates after reviewing TRAVERSE and other evidence. The clean takeaway is narrower than the hype: less blunt cardiovascular warning language, more specific monitoring, and still plenty of clinical caveats.
- Hot TakePublished June 22, 2026
Bicillin L-A Recovery Pushed to 2027 as Confusion Grows
Editorial commentary on STAT News, June 15, 2026
Bicillin L-A is still in national shortage, temporary Lentocilin importation is allowed, and recovery is now projected for late 2027. Testing can identify syphilis, but treatment access is the harder bottleneck.
- Hot TakePublished June 20, 2026
Father's Day Is a Good Excuse to Talk About Men's Lab Markers
Editorial commentary on Prenuvo, June 4, 2026
Prenuvo's men's healthspan article offers a timely Father's Day prompt: turn vague advice about men's health into a concrete lab-marker conversation, while keeping PSA and trend interpretation in context.
- Hot TakePublished June 19, 2026
Past Prediabetes Linked to Lasting CKM Risk, Study Finds
Editorial commentary on Frontiers in Endocrinology, June 16, 2026
A Kailuan cohort study found that people whose impaired fasting glucose later returned to normal still had higher CKM multimorbidity risk than people with sustained normal fasting glucose.
- Hot TakePublished June 17, 2026
Testosterone Prescribing Often Skips Recommended Testing
Editorial commentary on Endocrine Society, June 13, 2026
ENDO 2026 chart-review data found that only 12% of men receiving an initial testosterone prescription had the diagnostic workup described in Endocrine Society guidance.
- Hot TakePublished June 13, 2026
FDA Clears Home Urine Collection for Chlamydia and Gonorrhea Testing
Editorial commentary on OraSure Technologies, June 11, 2026
OraSure's Colli-Pee Dx Urine Collection Kit can now support at-home first-void urine collection for Roche cobas STI testing.
- Hot TakePublished June 12, 2026
ADA 2026: A1c Fell 1.6% on Average in Non-Insulin T2D
Editorial commentary on American Diabetes Association, June 6, 2026
Conference-presented CONNECT trial data found larger A1c reductions with continuous glucose monitoring in adults with type 2 diabetes who were not using insulin.
- Hot TakePublished June 10, 2026
ATA Revises Pregnancy Thyroid Guidelines After Nine Years
Editorial commentary on American Thyroid Association, June 3, 2026
The American Thyroid Association released its first major pregnancy thyroid guideline update since 2017, with new emphasis on repeat TSH testing and careful antibody interpretation.
- Hot TakePublished June 9, 2026
LabTestSuperstore.com Survey: Fear of Bad News Is Keeping Americans from the Lab
Editorial commentary on PR Newswire, June 9, 2026
Directional survey of U.S. adults finds that over 1 in 4 delayed or avoided bloodwork because they feared what the results might show.
- Hot TakePublished June 8, 2026
England's Herpes Diagnoses Rose While Other STIs Fell
Editorial commentary on UK Health Security Agency, June 5, 2026
UKHSA's 2025 surveillance data shows first episode genital herpes diagnoses rising 3.1% in England while overall STI diagnoses fell 8.3%. The signal is useful, but it should not be mistaken for a U.S. herpes wave.
- Hot TakePublished June 7, 2026
England's New STI Data: Syphilis Rose in Women in 2025
Editorial commentary on UK Health Security Agency, June 2, 2026
UKHSA's June 2026 surveillance release shows infectious syphilis falling overall in England in 2025, while diagnoses among women who have sex with men rose 4.8%. The signal is small in absolute numbers but useful for testing awareness.
- Hot TakePublished June 4, 2026
Lp(a) Plus Homocysteine Looks Worse Than Either Marker Alone in Premature Heart Attack Patients
Editorial commentary on Frontiers in Nutrition, June 2, 2026
A Frontiers in Nutrition prospective cohort of 2,284 premature MI patients found a stronger adverse-outcome signal when Lp(a) and homocysteine were both elevated. It is a risk-stratification finding, not a stand-alone screening rule.
- Hot TakePublished June 2, 2026
A New Gonorrhea Strain Is Causing Bloodstream Infections in Minnesota. Routine Testing Is the Off-Ramp.
Editorial commentary on Emerging Infectious Diseases (CDC), May 19, 2026
Minnesota Department of Health and CDC researchers describe a new Neisseria gonorrhoeae strain, ST16676, behind 26 of 28 disseminated gonococcal infections in the state in 2025. Routine NAAT-based STD testing catches gonorrhea at the mucosal stage, long before it can spread to the bloodstream.
- Hot TakePublished June 1, 2026
GRAIL Galleri Multi-Cancer Blood Test Cuts Stage IV Diagnoses in NHS Trial
Editorial commentary on American Society of Clinical Oncology Annual Meeting 2026 / GRAIL, May 31, 2026
The full NHS-Galleri trial results presented at ASCO 2026 missed the primary endpoint of cutting combined stage III and IV cancers, but cut stage IV diagnoses by more than 20 percent in the second and third screening rounds. The takeaway is genuinely mixed.
- Hot TakePublished May 30, 2026
GLP-1 Drugs Linked to Lower Metastasis Risk in Obesity-Related Cancers
Editorial commentary on Moffitt Cancer Center / American Society of Clinical Oncology 2026 Annual Meeting, May 29, 2026
An ASCO 2026 study of more than 12,000 patients linked GLP-1 drugs like semaglutide and tirzepatide to a 38 to 50 percent lower risk of metastatic disease in four obesity-related cancers compared with DPP-4 inhibitor users. The finding is observational, not causal.
- Hot TakePublished May 29, 2026
WHO Issues First Global Doxy-PEP Recommendation, With Mandatory Testing Built In
Editorial commentary on World Health Organization, May 28, 2026
The World Health Organization's May 28, 2026 doxy-PEP guidance is the first global recommendation of its kind. It bakes quarterly syphilis serology and bacterial STI panel testing into the protocol as required components, not optional add-ons.
- Hot TakePublished May 26, 2026
BMJ Meta-Analysis: Calcium and Vitamin D Do Little for Fractures in Average-Risk Older Adults
Editorial commentary on BMJ, May 21, 2026
A May 2026 BMJ meta-analysis of 69 trials and nearly 154,000 adults concluded that calcium, vitamin D, or both, given to average-risk older adults, offer little to no clinically meaningful benefit for fracture or fall prevention. The case for testing first instead of supplementing blindly is getting stronger.
- Hot TakePublished May 25, 2026
DoxyPEP May Be Losing Its Edge Against Gonorrhea, New Study Finds
Editorial commentary on The Lancet Infectious Diseases, May 7, 2026
A May 7, 2026 study in The Lancet Infectious Diseases found that doxyPEP protection against gonorrhea dropped sharply in Southern California as tetracycline-resistant strains spread, while protection against chlamydia and syphilis held.
- Hot TakePublished May 22, 2026
American Cancer Society Adds Blood Test to Colorectal Screening Options
Editorial commentary on American Cancer Society, May 21, 2026
The American Cancer Society's May 2026 update adds the Shield blood test to its colorectal cancer screening options. It is a real addition with real limits: lower sensitivity for precancerous polyps than colonoscopy or stool tests.
- Hot TakePublished May 20, 2026
Lp(a) Is an Independent Cardiovascular Risk Factor, And the VESALIUS-CV Data Just Reinforced It
Editorial commentary on Circulation / VESALIUS-CV Trial, May 12, 2026
VESALIUS-CV in Circulation, May 2026, found that Lp(a) is independently linked to major coronary events in primary-prevention patients with atherosclerosis or high-risk diabetes. The case for measuring it at least once in adulthood keeps getting stronger.
- Hot TakePublished May 18, 2026
FDA Approves Baxfendy for Resistant Hypertension. The Lab Story Behind It.
Editorial commentary on U.S. Food and Drug Administration / AstraZeneca, May 15, 2026
Baxfendy is a first-in-class aldosterone synthase inhibitor approved May 15, 2026 for difficult-to-control high blood pressure. The lab-relevant part of the story is how it changes ongoing electrolyte and kidney monitoring.
- Hot TakePublished May 16, 2026
ApoB Outperforms LDL for Guiding Cholesterol Therapy, New JAMA Study Finds
Editorial commentary on JAMA / Northwestern Medicine, May 13, 2026
A May 2026 JAMA Northwestern Medicine simulation found ApoB-guided cholesterol therapy outperformed LDL or non-HDL-guided care across a lifetime and was cost-effective. ApoB is finally getting its due.
- Hot TakePublished May 14, 2026
FDA Clears Onclarity HPV At-Home Self-Collection. The Cervical Screening Landscape Just Widened Again.
Editorial commentary on U.S. Food and Drug Administration / BD, April 23, 2026
The FDA cleared Onclarity's at-home HPV self-collection kit in April 2026, a year after Teal Wand. Cervical cancer screening at home is no longer a single-player market.
- Hot TakePublished May 11, 2026
High Lifelong Testosterone Linked to Coronary Artery Disease in Men, New Cambridge Study
Editorial commentary on University of Cambridge, February 10, 2026
A 2026 Cambridge genetic study of 1.4 million people found that men with gene variants linked to higher lifelong testosterone had a 17 percent greater risk of coronary artery disease, largely mediated by higher blood pressure. The finding is about endogenous testosterone, not TRT.
- Hot TakePublished May 7, 2026
What Blood Tests Do Astronauts Get? A Look at NASA Health Monitoring
Editorial commentary on NASA Human Research Program, May 7, 2026
A source-guided editorial explainer on the bloodwork and broader health monitoring NASA describes for astronauts before, during, and after spaceflight and why ordinary consumer labs are not an astronaut program in miniature.
- Hot TakePublished April 25, 2026
PSA Screening and Age: New Study Maps Overdiagnosis Risk
Editorial commentary on International Journal of Cancer, April 22, 2026
A new International Journal of Cancer study quantifies how PSA screening's overdiagnosis risk climbs with age, from 16% at 50 to 58% at 80. The data reinforces a clear age window where screening is most useful.